XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Jul. 30, 2013
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   $ 29,806,000 $ 24,364,000 $ 90,633,000 $ 62,793,000  
Deferred Revenue   6,897,000   6,897,000   $ 15,857,000
Drug product revenue recognized   29,806,000 24,364,000 90,633,000 62,793,000  
Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   23,256,000 13,371,000 42,137,000 28,733,000  
Drug product revenue recognized   23,256,000 13,371,000 42,137,000 28,733,000  
Drug Product Revenue [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   1,093,000 8,648,000 8,687,000 (168,000)  
Drug product revenue recognized   1,093,000 8,648,000 $ 8,687,000 (168,000)  
AstraZeneca Agreements [Member] | U.S./RoW [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront, non-contingent, non-refundable and time-based payments $ 1,200,000,000          
Additional consideration based on net sales description       low 20% range    
Aggregate consideration received excluding drug product revenue   439,000,000.0   $ 439,000,000.0    
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Drug Product Revenue [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   0 (6,700,000) 0 (2,200,000)  
Drug product revenue recognized   0 (6,700,000) 0 (2,200,000)  
AstraZeneca Agreements [Member] | China [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront, non-contingent, non-refundable and time-based payments $ 376,700,000          
Aggregate considerations received       77,200,000    
AstraZeneca Agreements [Member] | China [Member] | Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   19,700,000 11,800,000 36,000,000.0 22,200,000  
Drug product revenue recognized   19,700,000 11,800,000 36,000,000.0 22,200,000  
Direct Sales [Member] | Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   3,519,000 1,611,000 6,178,000 6,566,000  
Drug product revenue recognized   3,519,000 1,611,000 6,178,000 6,566,000  
Direct Sales [Member] | China [Member] | Product Revenue, Net [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Total revenue   3,500,000 1,600,000 6,200,000 6,600,000  
Drug product revenue recognized   $ 3,500,000 $ 1,600,000 $ 6,200,000 $ 6,600,000